Hypercalcemia is a common complication of cancer and occurs in 10—20% of patients. Although treatment of the underlying cancer is the optimal therapy, this may not be prac tical or available for many patients. This re port details our approach to the management of hypercalcemia at the British Columbia Can cer Agency, Vancouver Cancer Centre. The recommended approach to therapy is hydra tion followed by pamidronate and if needed, calcitonin. If no response is noted, plicamy cin may be used as a second line agent. In patients with multiple myeloma and lym phoma, prednisone is also suggested.
Ralston SH, Gallacher SJ, Patel U., Campbell J., Boyle ITCancer-associated hypercalcemia: morbidity and mortality. Ann Intern Med.1990;112:499-504.
2.
Gucalp R., Theriault R., Gill I., et al. Treatment of cancer-associated hypercalcemia. Arch Intern Med.1994;154:1935-1944.
3.
Theriault RLHypercalcemia of malignancy: pathophysiology and implications for treatment. Oncology.1993;7:47-50.
4.
Ritch PSTreatment of cancer-related hypercalcemia. Semin Oncol.1990;17(Suppl 5):26-33.
5.
Bilezikian JPManagement of acute hypercalcemia. New Engl J Med.1992;326:1196-1203.
6.
Chisholm MA, Mulloy AL, Taylor ATAcute management of cancer-related hypercalcemia. Ann Pharmacother.1996;30:507-513.
7.
Hall TG, Schaiff RAUpdate on the medical treatment of hypercalcemia of malignancy. Clin Pharm.1993;12:117-125.
8.
Armstrong DK , Ettinger DSCurrent approaches to treatment of hypercalcemia of malignancy. Modern Med.1990;45:226 -231.
9.
Mundy GREvaluation and treatment of hypercalcemia. Hosp Pract.1994;June:79-86.
10.
Ralston SH, Patel U., Fraser WD, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet.1989;2:1180-1182.
11.
Gucalp R., Ritch P., Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol.1992;10:134 -142.
12.
Kelihan MJ, Mangino PDPamidronate. Ann Pharmacother.1992 ; 26:1262-1269.
13.
Fitton A., McTavish D.Pamidronate. Drugs.1991;41:289-318.
14.
Nussbaum SR , Younger J., VandePol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med.1993 ;95:297-304.
15.
Morton AR, Cantrill JA, Craig AE, et al. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcemia of malignancy. Br Med J.1988 ;296:811-814.
16.
Plosker GL, Goa KLClodronate. a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs.1994;47:945-982.
17.
Fleisch H.Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcemic and metastatic bone disease. Drugs.1991;42:919-944.
18.
Singer FR, Ritch PS, Lad TE, et al. Treatment of hypercalcemia of malignancy with intravenous etidronate . Arch Intern Med.1991; 151:471-476.
19.
Flores JF, Rude RK, Chapman RA, et al. Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. Cancer.1994;73:2527-2534.
20.
Schaiff Rab , Hall TG, Bar RSMedical treatment of hypercalcemia. Clin Pharm.1989;8:108-121.
21.
Green L., Ringenberg QSCurrent concepts in the management of hypercalcemia of malignancy . Hosp Formul.1988 ;23:268-287.
22.
Coleman REComment: hypercalcemia of malignancy. Current medical literature. Breast Cancer . London: Royal Society of Medicine Service Ltd. 1990;2:3-9.
23.
Becker KLCorticosteroids: many of their side effects are really their actions . Drug Therapy.1982;Jan:131-139.
24.
Ralston SH, Dryburgh FJ, Cowan RA, et al. Comparison of aminohydroxypropylidene diphosphate, Mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcemia . Lancet.1985;2:907-910.
25.
Green L., Donehower RCHepatic toxicity of low doses of Mithramycin in hypercalcemia. Cancer Treat Rep.1984;68:1379-1381.
26.
Benedetti RG , Heilman KJ, Gabow PANephrotoxicity following single dose Mithramycin therapy. Am J Nephrol.1983;3: 277-278.
27.
Yamreudeewong W., Henann NE, Fazio A., et al. Possible severe thrombocytopenia associated with a single dose of plicamycin. Ann Pharmacother.1992;26:1369-1373.
